|
Attacking tumor blood vessels
MediGene’s EndoTAG®-1 represents an innovative therapeutic approach directed against newly developed tumor blood vessels, thereby suppressing tumor growth.
EndoTAG®-1 is a novel composition of paclitaxel combined with neutral and cationic lipids. The drug candidate attaches itself selectively to newly developed,
negatively charged endothelial cells in tumor blood vessels, thus attacking only the blood supply of tumors and not that of healthy tissue. By doing this, EndoTAG®-1
prevents the formation of new blood vessels in tumor tissue.
Compared to tumor cells, endothelial cells are genetically stable. MediGene assumes that due to this characteristic, EndoTAG®-1 can be used in the treatment of those
tumors that have already developed a resistance to conventional paclitaxel therapy.
MediGene has successfully provided proof of concept of EndoTAG®-1. A controlled phase II clinical trial for pancreatic cancer showed significantly increased survival
rates of those patients treated with EndoTAG®-1 and gemcitabine combination therapy. A phase II clinical trial in triple negative breast cancer also showed a positive
efficacy trend of EndoTAG®-1 combination therapy.
|
|
|
|
